BSH 2019 | Improved MRD response rates in CLL with obinutuzumab after ibrutinib exposure

Talha Munir

Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, speaks at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK. He discusses the results of the Bloodwise Trials Acceleration Programme (TAP) IciCLLe (ISRCTN12695354) extension study, which investigated the addition of obinutuzumab to ibrutinib in chronic lymphocytic leukemia (CLL), in patients who had and hadn’t had prior ibrutinib exposure.

Share this video